308 related articles for article (PubMed ID: 23508772)
1. The evolving role of biologics in the treatment of pediatric psoriasis.
Luu M; Cordoro KM
Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
[TBL] [Abstract][Full Text] [Related]
2. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
3. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
4. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
5. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
7. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
Moreno-Ramírez D
Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
[No Abstract] [Full Text] [Related]
8. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
9. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
10. Eosinophilia during psoriasis treatment with TNF antagonists.
Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
[No Abstract] [Full Text] [Related]
11. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
12. Treatment of generalized vitiligo with anti-TNF-α Agents.
Alghamdi KM; Khurrum H; Taieb A; Ezzedine K
J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
14. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
18. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
19. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
20. Switching biologics for psoriasis.
Ormerod AD
Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
